Search Results

Blueprint has a next-generation systemic mastocytosis treatment, called elenestinib, that Sanofi CEO Paul Hudson told analysts provides an “opportunity to grow through the ‘30s.”

Blueprint Medicines Corporation, announced that, effective May 1, 2024, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 6,400 shares of its common stock and an aggregate of 3,200 restricted stock units to two new employees under Blueprint Medicines’ 2020 Inducement Plan.

Blueprint Medicines Corporation, announced that, effective April 1, 2024, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 3,711 shares of its common stock and an aggregate of 1,854 restricted stock units to three new employees under Blueprint Medicines’ 2020 Inducement Plan.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase the company’s research and development strategy.

Blueprint Medicines Corporation reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023 and provided financial guidance.

Blueprint Medicines Corporation, announced that, effective February 1, 2024, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 1,717 shares of its common stock and an aggregate of 858 restricted stock units to three new employees under Blueprint Medicines’ 2020 Inducement Plan.